Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 245

1.

HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.

Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG.

Cancer Immunol Immunother. 2010 Jun;59(6):943-53. doi: 10.1007/s00262-010-0820-6. Epub 2010 Feb 6.

2.

Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.

Johnson LE, McNeel DG.

Prostate. 2012 May 15;72(7):730-40. doi: 10.1002/pros.21477. Epub 2011 Aug 30.

PMID:
22529020
3.

CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.

Olson BM, McNeel DG.

Cancer Immunol Immunother. 2011 Jun;60(6):781-92. doi: 10.1007/s00262-011-0987-5. Epub 2011 Feb 25.

4.

Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.

Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L.

Cancer Res. 2005 Jul 15;65(14):6435-42.

5.

DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.

Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG.

J Immunother. 2010 Jul-Aug;33(6):639-47. doi: 10.1097/CJI.0b013e3181dda23e.

6.

Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy.

Matsueda S, Wang M, Weng J, Li Y, Yin B, Zou J, Li Q, Zhao W, Peng W, Legras X, Loo C, Wang RF, Wang HY.

PLoS One. 2012;7(9):e45756. doi: 10.1371/journal.pone.0045756. Epub 2012 Sep 20.

7.

Identification of T helper epitopes from prostatic acid phosphatase.

McNeel DG, Nguyen LD, Disis ML.

Cancer Res. 2001 Jul 1;61(13):5161-7.

8.

Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.

Smith HA, McNeel DG.

J Immunother. 2011 Oct;34(8):569-80. doi: 10.1097/CJI.0b013e31822b5b1d.

9.

DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.

Smith HA, Rekoske BT, McNeel DG.

Vaccine. 2014 Mar 26;32(15):1707-15. doi: 10.1016/j.vaccine.2014.01.048. Epub 2014 Jan 31.

10.

Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.

Saif JM, Vadakekolathu J, Rane SS, McDonald D, Ahmad M, Mathieu M, Pockley AG, Durrant L, Metheringham R, Rees RC, McArdle SE.

Eur J Immunol. 2014 Apr;44(4):994-1004. doi: 10.1002/eji.201343863. Epub 2014 Mar 7.

11.

Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans.

Geluk A, van Meijgaarden KE, Franken KL, Drijfhout JW, D'Souza S, Necker A, Huygen K, Ottenhoff TH.

J Immunol. 2000 Dec 1;165(11):6463-71.

12.

Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.

Klyushnenkova EN, Kouiavskaia DV, Kodak JA, Vandenbark AA, Alexander RB.

Prostate. 2007 Jul 1;67(10):1019-28.

PMID:
17455230
13.

Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.

Oh S, Terabe M, Pendleton CD, Bhattacharyya A, Bera TK, Epel M, Reiter Y, Phillips J, Linehan WM, Kasten-Sportes C, Pastan I, Berzofsky JA.

Cancer Res. 2004 Apr 1;64(7):2610-8.

14.

Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.

Chakraborty NG, Stevens RL, Mehrotra S, Laska E, Taxel P, Sporn JR, Schauer P, Albertsen PC.

Cancer Immunol Immunother. 2003 Aug;52(8):497-505. Epub 2003 Jun 3.

PMID:
12783216
15.

An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.

Nielsen JS, Wick DA, Tran E, Nelson BH, Webb JR.

J Immunol Methods. 2010 Aug 31;360(1-2):149-56. doi: 10.1016/j.jim.2010.07.003. Epub 2010 Jul 15.

PMID:
20637775
16.

[Estimation of an NY-ESO-1 expressing HCC cell line by NY-ESO-1b specific CD8+T cells in vitro induced by HLA-A2 restricted NY-ESO-1b peptide].

Qiao H, Qian XP, Zhang HG, Tian C, Chen WF.

Beijing Da Xue Xue Bao. 2005 Dec 18;37(6):565-8. Chinese.

17.

Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.

Peng S, Trimble C, He L, Tsai YC, Lin CT, Boyd DA, Pardoll D, Hung CF, Wu TC.

Gene Ther. 2006 Jan;13(1):67-77.

18.

Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.

Kissick HT, Sanda MG, Dunn LK, Arredouani MS.

PLoS One. 2014 Apr 1;9(4):e93231. doi: 10.1371/journal.pone.0093231. eCollection 2014.

19.

ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.

Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AM, Lemonnier FA, Kosmatopoulos K, Gambacorti-Passerini C.

Blood. 2002 Mar 15;99(6):2100-6.

20.

A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.

Tu SH, Huang HI, Lin SI, Liu HY, Sher YP, Chiang SK, Chong P, Roffler S, Tseng GC, Chen HW, Liu SJ.

J Immunother. 2012 Apr;35(3):235-44. doi: 10.1097/CJI.0b013e318248f2ae.

PMID:
22421941

Supplemental Content

Support Center